Webinars and Tutorials

CAR T Cell Therapy for Refractory and Early Relapsed DLBCL - Part 1: Practical Approaches to Delivering CAR T-Cell Therapy in 2L LBCL

CAR T Cell Therapy for Refractory and Early Relapsed DLBCL - Part 1: Practical Approaches to Delivering CAR T-Cell Therapy in 2L LBCL

Overview

Speakers:
Dr. Ronan Foley
Dr. John Kuruvilla
20.11.2024
Duration: 18 mins 28 secs

During this discussion, Canadian CAR T experts review pivotal trial and current real-world evidence supporting use of CAR T cell for patients with large B-cell lymphoma (LBCL), with a focus on treatment in the second-line (2L) setting. Experts also discuss key clinical and practical considerations for all stages of the 2L CAR T journey, including synergies between referral and treatment centres.

Click here to evaluate this content

CAR T Cell Therapy for Refractory and Early Relapsed DLBCL - Part 2: 2L CAR T for Primary Refractory LBCL

CAR T Cell Therapy for Refractory and Early Relapsed DLBCL - Part 2: 2L CAR T for Primary Refractory LBCL

Overview

Speakers:
Dr. Ronan Foley
Dr. John Kuruvilla
20.11.2024
Duration: 13 mins 13 secs

In this video, Canadian CAR T experts review a clinical case of primary refractory LBCL. During this discussion, the experts review key clinical and logistical aspects for all stages of the 2L CAR T journey for patients with primary refractory LBCL, including patient eligibility and preparation.

Click here to evaluate this content

CAR T Cell Therapy for Refractory and Early Relapsed DLBCL - Part 3: 2L CART for Primary Progressive LBCL

CAR T Cell Therapy for Refractory and Early Relapsed DLBCL - Part 3: 2L CART for Primary Progressive LBCL

Overview

Speakers:
Dr. Ronan Foley
Dr. John Kuruvilla
20.11.2024
Duration: 16 mins 3 secs

In this video, Canadian CAR T experts review a clinical case of primary progressive LBCL. During this discussion, the experts review key clinical and logistical aspects for all stages of the 2L CAR T journey for patients with primary progressive LBCL, including the role of holding/bridging therapy and the importance of quick communication between referral and treatment centres.

Click here to evaluate this content

CAR T Cell Therapy for Refractory and Early Relapsed DLBCL - Part 4: 2L CART for early relapsed (<12 months) LBCL

CAR T Cell Therapy for Refractory and Early Relapsed DLBCL - Part 4: 2L CART for early relapsed (<12 months) LBCL

Overview

Speakers:
Dr. Ronan Foley
Dr. John Kuruvilla
20.11.2024
Duration: 17 mins 34 secs

In this video, Canadian CAR T experts review a clinical case of early relapsed (<12 months) LBCL. During this discussion, the experts review key clinical and logistical aspects for all stages of the 2L CAR T journey for patients with early relapsed (<12 months) LBCL, including the importance of re-biopsy and of referral and treatment centres partnership.

Click here to evaluate this content

Expert Discussion on CAR T Therapy for Relapsed and Refractory Mantle Cell Lymphoma

Expert Discussion on CAR T Therapy for Relapsed and Refractory Mantle Cell Lymphoma

Overview

Speakers:
Charles Herbaux, MD, PhD
01.01.2023
Duration: 32 mins 14 secs

In this video, Dr. Herbaux highlights emerging data and discusses his experience on the management of patients with R/R MCL. Specifically, he reviews clinical data and real-world evidence for CAR T therapy in R/R MCL, shares best-practices on patient identification, disease monitoring and management prior to CAR T infusion as well as long-term patient care post-infusion.

Click here to evaluate this content